<description>&lt;p&gt;&lt;span style= "font-size: 11.0pt; line-height: 115%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about a new selective dopamine agonist for people with Parkinson's disease, the use of artificial intelligence in preparing journal manuscripts, and caffeinated coffee's role in reducing dementia risk.&lt;/span&gt;&lt;/p&gt;</description>

Neurology Today in 5

American Academy of Neurology

New Dopamine Agonist for Parkinson's, Artificial Intelligence in Medical Journals, Coffee and Dementia Risk

MAY 21, 20264 MIN
Neurology Today in 5

New Dopamine Agonist for Parkinson's, Artificial Intelligence in Medical Journals, Coffee and Dementia Risk

MAY 21, 20264 MIN

Description

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about a new selective dopamine agonist for people with Parkinson's disease, the use of artificial intelligence in preparing journal manuscripts, and caffeinated coffee's role in reducing dementia risk.